CA102N + trifluridine + tipiracil

CA102N + trifluridine + tipiracil is a **combination therapy** under investigation primarily for advanced or metastatic solid tumors, notably metastatic colorectal cancer. **CA102N** is a covalently bound conjugate of modified nimesulide and sodium hyaluronate (NaHA). It uses the HA's affinity for the CD44 receptor, frequently overexpressed in colorectal cancer, to target tumors for **targeted delivery of nimesulide**. **Trifluridine** is a nucleoside analog incorporated into DNA, causing dysfunction and cytotoxicity, while **tipiracil** is a thymidine phosphorylase inhibitor that increases the bioavailability of trifluridine by slowing its degradation. Clinical studies indicate the triplet is safe, well-tolerated, and shows early evidence of antitumor activity; further development is ongoing[1][4][5][6][7].

Other names

trifluridine/tipiracilFTD/TPI